OMERS ADMINISTRATION Corp Makes New $943,000 Investment in Simulations Plus, Inc. $SLP

OMERS ADMINISTRATION Corp bought a new position in Simulations Plus, Inc. (NASDAQ:SLP) during the second quarter, Holdings Channel.com reports. The firm bought 51,500 shares of the technology company’s stock, valued at approximately $943,000.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Simulations Plus during the second quarter valued at approximately $25,000. Quarry LP bought a new stake in Simulations Plus during the third quarter worth $28,000. GAMMA Investing LLC boosted its position in Simulations Plus by 26.0% in the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock worth $52,000 after purchasing an additional 585 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Simulations Plus by 59.3% in the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock worth $53,000 after purchasing an additional 1,669 shares during the last quarter. Finally, Fifth Third Bancorp bought a new position in Simulations Plus in the 1st quarter valued at $54,000. 78.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SLP shares. William Blair lowered Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Weiss Ratings raised shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th. Craig Hallum lowered shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target for the company. in a research report on Thursday, June 18th. Finally, Wall Street Zen downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Seven equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average target price of $17.25.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 4,177 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the transaction, the director owned 3,202,131 shares in the company, valued at approximately $59,047,295.64. This represents a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.10% of the company’s stock.

Simulations Plus Trading Up 0.1%

Simulations Plus stock opened at $18.42 on Friday. Simulations Plus, Inc. has a 12 month low of $11.09 and a 12 month high of $21.01. The business’s 50 day simple moving average is $18.30 and its 200 day simple moving average is $15.39. The company has a market cap of $372.54 million, a price-to-earnings ratio of 46.05 and a beta of 1.32.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.07. The business had revenue of $21.89 million during the quarter, compared to the consensus estimate of $20.90 million. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.

Simulations Plus Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.